Biomoda expands patent portfolio of lung cancer diagnostics

Biomoda’s innovative, non-invasive technology is designed for early lung cancer screening of large populations at a reasonable cost. With the technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope.

Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease at more advanced stages. Biomoda’s technology is said to complement these tools by screening for signs of lung cancer at an earlier stage, ensuring that patients receive advanced tests at the appropriate time.

John Cousins, Biomoda president, said: “Our way is now cleared for actively expanding our patent portfolio and collaborating with international partners interested in the development and use of non-invasive early-stage cancer detection technology.”